Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486805 | 0.87 | BDKRB2 (0.49) | BDKRB2HPGDNPC1RAB9ATSHR | |
| SCHEMBL7684987 | 0.85 | PTGS1 (0.57) | BDKRB2HPGDNPC1RAB9ATSHR | |
| SCHEMBL11809650 | 0.83 | CXCL8 (0.43) | BDKRB2HPGDNPC1RAB9ATSHR | |
| SCHEMBL11814511 | 0.82 | ALDH1A1 (0.48) | BDKRB2HPGDNPC1RAB9ATSHR | |
| SCHEMBL17486803 | 0.79 | CXCL8 (0.57) | BDKRB2HPGDNPC1RAB9APTGS1 | |
| SCHEMBL7674645 | 0.77 | PGR (0.46) | HPGDNPC1RAB9ATSHRHPGDS | |
| SCHEMBL11446810 | 0.77 | BDKRB2 (0.43) | BDKRB2HPGDNPC1RAB9ATSHR | |
| SCHEMBL11808758 | 0.75 | CXCL8 (0.72) | BDKRB2HPGDPTGS1PTGS2CXCL8 | |
| SCHEMBL11446809 | 0.75 | HPGD (0.42) | BDKRB2HPGDNPC1RAB9ATSHR | |
| SCHEMBL11814111 | 0.74 | ALDH1A1 (0.47) | BDKRB2HPGDNPC1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | SHIRE HUMAN GENETIC THERAPIES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | SHIRE HUMAN GENETIC THERAPIES, INC. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030416-A1 | METHODS OF TREATING B2-BRADYKININ RECEPTOR MEDIATED ANGIOEDEMA | BDKRB2, BDKRB1, HRH2 | BDKRB2 1/4885HPGD 111/4885NPC1 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.